Literature DB >> 34426069

Oral epithelioid rhabdomyosarcoma: Report of a rare case and literature review of a distinct variant of rhabdomyosarcoma.

Carla Isabelly Rodrigues-Fernandes1, Celeste Sánchez-Romero2, Oslei Paes de Almeida3, Fábio de Abreu Alves4, Elaine Judite de Amorim Carvalho5, Jurema Freire Lisboa de Castro5, Danyel Elias da Cruz Perez5.   

Abstract

Epithelioid rhabdomyosarcoma is a new and rare morphological variant of rhabdomyosarcoma, with only a few reports in the literature. We aimed to describe an atypical case of this variant involving the oral cavity. A 33-year-old male patient presented with an asymptomatic, gingival mass adjacent to the left maxillary canine with progressive growth over approximately 3 months. Microscopic and immunohistochemical assessment of the biopsy specimen were consistent with epithelioid rhabdomyosarcoma. After initial chemotherapy and radiotherapy, the patient had a partial response. Surgical resection was performed, followed by adjuvant chemotherapy. After local and distant recurrences, the patient died 22 months after the initial diagnosis. According to the literature, epithelioid rhabdomyosarcoma still lacks data regarding its aetiologic factors and therapeutic options. Whether this tumour is a true subtype or simply a variant of other subtypes of rhabdomyosarcoma also remains unconfirmed. Final diagnosis leads to a broad array of microscopic and immunohistochemical analyses.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaplastic lymphoma kinase; Epithelioid cells; Gingiva; Mouth; Rhabdomyosarcoma

Mesh:

Year:  2021        PMID: 34426069     DOI: 10.1016/j.oraloncology.2021.105498

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  1 in total

Review 1.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.